UK – Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces the appointment of Nick Kerton as Chief Executive Officer of the Company and of Nick Walters as Chief Financial Officer, succeeding Ruth Keir and David Blair respectively, who have resigned from the Company.
Dr. Nick Kerton became a Non-Executive Director of Cambridge Cognition prior to the Company’s Admission to AIM in April 2013 and has significant experience in management positions within the healthcare sector and of delivering investor returns. Most recently, Nick led the Sirigen Group from initial venture capital funding in 2008 through to the sale of the business in August 2012, delivering a return to investors of between 2.5x-4.0x on their original investment. Nick was commercial director within the management team who established Celsis International PLC, one of the first biotechnology companies to float on the London Stock Exchange, led the successful sale of Maybridge to Fisher Scientific International and founded Lab21 (a molecular diagnostics service).
Nick Walters, a chartered accountant, joins the Company as Chief Financial Officer with over thirty years’ experience in finance roles and board-level appointments. Nick worked closely with Dr. Nick Kerton at Sirigen Group and Maybridge. Information in respect of Nick required pursuant to Schedule 2(g) of the AIM Rules for Companies are set out below.
The Company looks forward to announcing its interim results for the six months ended 30 June 2013 on 18 September 2013.
Jane Worlock, chairman, commented that “Ruth and David leave the business at the end of the month with our best wishes and gratitude for their contribution to establishing the firm footing on which we today stand and for their tireless work in leading us through to a successful admission to AIM. As we move into the next phase of our development the time was right for Ruth and David to hand over the reins to a new management team who will lead the Company through its next stage of development and growth. Our two core businesses in the academic and pharmaceutical clinical trials sectors are considered industry leaders, whilst CANTABmobile, our mobile solution for the early detection of dementia in primary healthcare environments, continues to gather traction.
“Nick Kerton has significant experience of driving forward companies and products at this stage in their development and we are excited by our prospects under his leadership. I am therefore very pleased that both Nick Kerton and Nick Walters have accepted these appointments and look forward to working with them.”
Nick Kerton commented “I look forward to working with the team at Cambridge Cognition to take the business through the next stage of its development. Cambridge Cognition is an outstanding business and recognised by its peers for the quality of its team and products.”
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
